New universal flu vaccine offers protection against multiple strains

Image
IANS New York
Last Updated : Aug 26 2018 | 7:25 PM IST

A universal flu vaccine with a strong antibody response, that could protect people against most influenza strains, is one step close to reality, a study has revealed.

Experiments performed on mice showed that the vaccine elicited a strong antibody response to a structure on the surface of flu viruses, called the hemagglutinin (HA) and protected them from infection by various flu strains.

Unlike the seasonal flu vaccines that are updated every year, the new vaccine can also be given a few times over a lifetime to provide protection potentially similar to a tetanus vaccine.

"This vaccine was able to do something that most other candidate flu vaccines have not been able to do," said study co-senior author Drew Weissman, Professor at the University of Pennsylvania in the US.

"If it works in humans even half as well as it does in mice, then the sky's the limit -- it could be something that everyone uses in the future to protect themselves from the flu," added Scott Hensley, Associate Professor at the varsity.

The findings are described in the journal Nature Communications.

As opposed to the seasonal flu vaccines, the new vaccine does not directly use flu HA proteins, instead, it uses mRNA molecules that encode HA proteins to elicit an antibody response.

When injected into a recipient, these RNAs are taken up by immune system dendritic cells and translated into copies of the HA protein by the protein-making machinery within those cells.

This within-cell production of viral proteins does a better job of mimicking a real flu infection and elicits a very powerful protective antibody response, the researchers explained.

The team observed that after immunisation, these strong antibody responses to the vaccine persisted through thirty weeks of the experiment.

In addition to the mice, the researchers successfully repeated these experiments in ferrets and rabbits, other species commonly used as vaccine-development animal models.

--IANS

asj/rt/mag/sed

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Aug 26 2018 | 7:18 PM IST

Next Story